| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
22,790,000 |
| Market
Cap: |
24.16(M) |
| Last
Volume: |
563,483 |
Avg
Vol: |
252,607 |
| 52
Week Range: |
$0.502 - $7 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Durect is a biopharmaceutical company developing therapies derived from its Epigenetic Regulator Program. Larsucosterol (also known as DUR-928), a chemical entity in clinical development, is the primary candidate in Co.'s Epigenetic Regulator Program. A bioavailable small molecule, larsucosterol has been shown in both in vitro and in vivo studies to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival. Co. is conducting a double-blind, placebo-controlled Phase 2b clinical trial called AHFIRM, in which Co. is evaluating larsucosterol's life saving potential in patients with severe alcohol-associated hepatitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
482,093 |
| Total Buy Value |
$0 |
$0 |
$0 |
$288,249 |
| Total People Bought |
0 |
0 |
0 |
4 |
| Total Buy Transactions |
0 |
0 |
0 |
15 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Theeuwes Felix |
Chairman and CSO |
• • – |
2013-11-08 |
4 |
B |
$1.40 |
$999,999 |
D/D |
714,285 |
714,285 |
2.81 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2013-09-10 |
4 |
B |
$1.19 |
$90,123 |
I/I |
75,000 |
1,637,714 |
2.66 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2013-09-09 |
4 |
B |
$1.14 |
$28,873 |
I/I |
25,000 |
1,562,714 |
2.66 |
- |
|
| Brown James E |
President & CEO |
• • – |
2013-06-04 |
4 |
B |
$0.78 |
$24,102 |
I/I |
30,000 |
590,000 |
2.58 |
- |
|
| Saxe Jon S |
Director |
– • – |
2012-12-12 |
4 |
B |
$0.91 |
$13,619 |
D/D |
15,000 |
27,810 |
2.39 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2012-12-11 |
4 |
GD |
$0.00 |
$0 |
I/I |
756,000 |
1,537,714 |
|
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2012-11-14 |
4 |
B |
$0.98 |
$4,312 |
I/I |
4,400 |
2,282,714 |
2.58 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2012-11-13 |
4 |
B |
$1.00 |
$96,786 |
I/I |
95,600 |
2,278,314 |
2.66 |
- |
|
| Yum Su Il |
Exec. VP Pharm./R&D |
• – – |
2012-10-17 |
4 |
OE |
$0.78 |
$57,294 |
D/D |
73,454 |
73,454 |
|
- |
|
| Saxe Jon S |
Director |
– • – |
2012-08-28 |
4 |
B |
$0.98 |
$4,900 |
D/D |
5,000 |
12,810 |
2.31 |
- |
|
| Saxe Jon S |
Director |
– • – |
2012-08-27 |
4 |
B |
$0.96 |
$2,698 |
D/D |
2,810 |
7,810 |
2.31 |
- |
|
| Saxe Jon S |
Director |
– • – |
2012-08-23 |
4 |
B |
$1.00 |
$5,000 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Neukernons Arnand |
Director |
– • – |
2012-06-14 |
4 |
B |
$0.88 |
$6,333 |
I/I |
7,200 |
95,000 |
2.1 |
- |
|
| Neukernons Arnand |
Director |
– • – |
2012-06-14 |
4 |
B |
$0.82 |
$5,978 |
I/I |
7,100 |
82,100 |
2.1 |
- |
|
| Neukernons Arnand |
Director |
– • – |
2012-06-14 |
4 |
B |
$0.85 |
$4,888 |
I/I |
5,700 |
87,800 |
2.1 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2012-05-14 |
4 |
B |
$0.78 |
$27,611 |
I/I |
35,000 |
2,182,714 |
2.66 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2012-05-11 |
4 |
B |
$0.78 |
$31,585 |
I/I |
40,000 |
2,147,714 |
2.66 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2012-05-10 |
4 |
B |
$0.75 |
$450 |
I/I |
600 |
2,107,714 |
2.58 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2012-05-10 |
4 |
B |
$0.74 |
$52,966 |
I/I |
68,740 |
2,107,114 |
2.66 |
- |
|
| Hoffmann Dave |
Director |
– • – |
2012-05-10 |
4 |
B |
$0.79 |
$20,235 |
D/D |
25,000 |
25,000 |
2.39 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2012-05-09 |
4 |
B |
$0.74 |
$34,438 |
I/I |
45,773 |
2,038,374 |
2.66 |
- |
|
| Brown James E |
President & CEO |
• • – |
2012-03-14 |
4 |
B |
$0.78 |
$15,784 |
I/I |
20,000 |
20,000 |
2.58 |
- |
|
| Brown James E |
President & CEO |
• • – |
2011-11-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
1,764,530 |
|
- |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2011-01-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
184,627 |
|
- |
|
| Blaschke Terrence F |
Director |
– • – |
2010-12-01 |
4 |
B |
$3.16 |
$9,480 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
152 Records found
|
|
Page 4 of 7 |
|
|
0.07 (6.19%) 
